Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
MET promoted the development of squamous tumors by stimulating the synthesis and release of ligands that activate the epidermal growth factor receptor (EGFR (show EGFR Antibodies)).
through the activation of EGFR, MET activation parallels a RAS pathway to contribute to human and mouse cutaneous cancers.
There are 2 categories of MET gene amplification in lung cancer patients, de novo and that secondary to TKI therapy. These patients can benefit from MET inhibitor therapy. Dual mechanisms of resistance, EGFR T790M mutation and c-MET amplification after TKI therapy, may suggest a poor prognosis.
MET amplification is here identified-clinically and preclinically-as a new mechanism of resistance to EGFR (show EGFR Antibodies) and BRAF (show BRAF Antibodies) dual/triple block combinations in BRAF (show BRAF Antibodies)-mutated colorectal cancer. Switching from EGFR (show EGFR Antibodies) to MET inhibition, while maintaining BRAF (show BRAF Antibodies) inhibition, resulted in clinical benefit after the occurrence of MET-driven acquired resistance.
Which control critical events for colonization such as HGF (show HGF Antibodies)/Met axis and Wwox (show WWOX Antibodies), as therapy of bone metastasis.
Data show that by reducing CD82, KSHV miR-K6-5p expedites cell invasion and angiogenesis by activating the c-Met pathway.
These results suggest MET overexpression is related to altered c-CBL (show CBL Antibodies) expression in head and neck squamous cell carcinoma, which may influence tumorigenesis
Authors characterized exosomes from GBM cells harbouring and not harbouring PTPRZ1 (show PTPRZ1 Antibodies)-MET fusion (ZM fusion).
Data demonstrated that c-Met activation increases miR (show MLXIP Antibodies)-130b levels, inhibits androgen receptor (show AR Antibodies) expression, promotes cancer spreading and resistance to hormone ablation therapy.
The role of the EGFR (show EGFR Antibodies) and Met interaction in glioblastoma.The role of MET in the glioblastoma resistance to treatment. [review]
possible cooperative role of the EGF (show EGF Antibodies) and HGF (show HGF Antibodies) pathways and indicate that cross-talk between their respective receptors may modulate mammary gland development in the cow
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene.
, HGF/SF receptor
, SF receptor
, hepatocyte growth factor receptor
, met proto-oncogene tyrosine kinase
, proto-oncogene c-Met
, scatter factor receptor
, tyrosine-protein kinase Met
, HGF receptor c-Met
, hepatocyte growth factor
, hepatoCyte growth factor receptor
, met proto-oncogene
, Hepatocyte growth factor receptor
, hepatocyte growth factor receptor-like
, Proto-oncogene c-Met
, Scatter factor receptor
, Tyrosine-protein kinase Met